Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?

@article{Pan2007MetabolicTA,
  title={Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?},
  author={James G. Pan and Tak Wah Mak},
  journal={Science's STKE},
  year={2007},
  volume={2007},
  pages={pe14 - pe14}
}
As a result of a spectrum of mitochondrial defects, tumor cells often preferentially use glycolysis to generate adenosine triphosphate (ATP), even in the presence of oxygen, a phenomenon known as aerobic glycolysis, or the "Warburg effect." Dichloroacetate (DCA) is an inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase (PDH), a gatekeeping enzyme for the entry of pyruvate into the mitochondrial tricarboxylic acid (TCA) cycle. In mice, DCA… Expand
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
TLDR
The generic drug dichloroacetate is an orally available small molecule that reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Expand
Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?
TLDR
The fact that DCA has better in vivo activity than in vitro activity suggests that there are unique aspects of solid tumor growth and metabolism that are difficult to recapitulate in vitro and may be important in determining the effectiveness of this class of drugs. Expand
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin.
TLDR
It is reported that all acute leukemia subtypes demonstrated growth arrest and cell death when treated the novel glycolysis inhibitor 3-BrOP. Expand
Review of aerobic glycolysis and its key enzymes – new targets for lung cancer therapy
TLDR
The discovery of aerobic glycolysis in the 1920s has provided new means and potential therapeutic targets for lung cancer, and can be regulated by many oncoproteins to promote tumor proliferation, migration, and metastasis with dependence or independence of gly colysis. Expand
AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells.
TLDR
Molecular targeting of mitochondrial oxidative metabolism in liver cancer cells by AAV3-mediated delivery of pda1 holds promise as a novel and effective therapeutic approach for human hepatic tumors. Expand
The Warburg effect: molecular aspects and therapeutic possibilities
TLDR
There is certainly a strong link between the genetic factors, epigenetic modulation, cancer immunosurveillance and the Warburg effect, which will be discussed in this review. Expand
The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis.
TLDR
It is demonstrated that 5-aminolevulinic acid inhibits the Warburg effect and induces cancer cell death, and use of this endogenous compound might constitute a novel approach to cancer therapy. Expand
3-bromopyruvate: Targets and outcomes
  • M. Shoshan
  • Biology, Medicine
  • Journal of Bioenergetics and Biomembranes
  • 2012
TLDR
It is suggested that the very range of possible targets of 3-BP, which pertain to the altered energy metabolism of tumor cells, contributes both to the efficacy and the tumor specificity of the drug. Expand
Metabolic Modulation of Glioblastoma with Dichloroacetate
TLDR
Dichloroacetate appears to be safe to give to humans at doses that are required for pyruvate dehydrogenase inhibition, and can be added to a growing group of metabolic modulators that may prove useful in cancer therapy. Expand
Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression
TLDR
The study suggests that LDH and complex I play distinct roles in regulating glycolysis and cell proliferation, and inhibition of these two augments synthetic lethality in melanoma. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Glycolysis inhibition for anticancer treatment
TLDR
The increased dependence of cancer cells on glycolytic pathway for ATP generation provides a biochemical basis for the design of therapeutic strategies to preferentially kill cancer cells by pharmacological inhibition of Glycolysis. Expand
p53 Regulates Mitochondrial Respiration
TLDR
It is shown that p53, one of the most frequently mutated genes in cancers, modulates the balance between the utilization of respiratory and glycolytic pathways, and Synthesis of Cytochrome c Oxidase 2 (SCO2) is identified as the downstream mediator of this effect. Expand
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.
TLDR
The unique metabolic profile of cancer (aerobic glycolysis) might confer apoptosis resistance and be therapeutically targeted and the orally available DCA is a promising selective anticancer agent. Expand
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.
TLDR
It is demonstrated that LDH-A plays a key role in tumor maintenance as well as stimulation of mitochondrial respiration and decrease of mitochondrial membrane potential in malignant cells. Expand
Characterization of a novel metabolic strategy used by drug‐resistant tumor cells
  • M. Harper, A. Antoniou, +18 authors M. Newell
  • Medicine, Biology
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2002
TLDR
It is shown that drug‐resistant cells have low mitochondrial membrane potential, use nonglucose carbon sources (fatty acids) for mitochondrial oxygen consumption when glucose becomes limited, and are protected from exogenous stress such as radiation. Expand
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
TLDR
A hypoxia-induced metabolic switch that shunts glucose metabolites from the mitochondria to glycolysis to maintain ATP production and to prevent toxic ROS production is revealed. Expand
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
  • Y. Liu
  • Medicine
  • Prostate Cancer and Prostatic Diseases
  • 2006
TLDR
Dominant fatty acid metabolism rather than glycolysis has the potential to be the basis for imaging diagnosis and targeted treatment of prostate cancer. Expand
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
TLDR
expression of TIGAR may modulate the apoptotic response to p53, allowing survival in the face of mild or transient stress signals that may be reversed or repaired, and the decrease of intracellular ROS levels in response to TIGar may also play a role in the ability of p53 to protect from the accumulation of genomic damage. Expand
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
TLDR
Surprisingly, a new molecular target and a potential new application for Orlistat are found, a novel inhibitor of the thioesterase domain of fatty acid synthase, an enzyme strongly linked to tumor progression. Expand
Why do cancers have high aerobic glycolysis?
TLDR
It is proposed that persistent metabolism of glucose to lactate even in aerobic conditions is an adaptation to intermittent hypoxia in pre-malignant lesions, which leads to microenvironmental acidosis requiring evolution to phenotypes resistant to acid-induced cell toxicity. Expand
...
1
2
3
4
5
...